MapLight Therapeutics, Inc.
ML-007C-MA
schizophrenia
Countdown
40days
Phase 2 readout · Aug 15, 2026
What's at stake
Phase 2 trial results for ML-007C-MA in schizophrenia are due Aug 15, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“The Company remains well capitalized ahead of the topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA in schizophrenia, expected by mid-August 2026.”